Massive study aims to crack the code of KRAS-Mutant pancreatic cancer

NCT ID NCT07557849

Recruiting now Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is creating a large database of 1,000 people with KRAS-mutant pancreatic cancer who are receiving targeted therapy. Researchers will track how long patients live and how long their cancer stays under control. The goal is to learn which treatments work best for different KRAS mutation subtypes, paving the way for more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better match pancreatic cancer patients with the right targeted therapies based on their specific KRAS mutation.
What could go wrong: This is an observational study, not a treatment trial. It won't directly test a new drug, and results may take years to influence patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Department of Pancreatic Surgery
RECRUITING

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.